Studies have shown that PPARγ can inhibit VEGF transcription-induced tumor angiogenesis by binding to the receptor responsive element (PPRE) in the VEGF promoter region in vitro, decrease the VEGF receptor expression in vascular endothelial cells, and suppress tumor angiogenesis (Wagner and Wagner 2020). Here, PPARG is linked to neoplasm.